跳至主要内容
临床试验/JPRN-UMIN000041182
JPRN-UMIN000041182招募中2 期

A single center Phase II study for the safety and efficacy of upfront high dose chemotherapy with thiotepa and busulfan followed by autologous peripheral blood stem cell transplantation for primary central nervous system lymphoma. - P2 clinical trial of TT/BU with auto-PBSCT for PCNS

Ogaki municipal hospital0 个研究点目标入组 10 人开始时间: 2020年8月17日最近更新:

试验速览

阶段
2 期
状态
招募中
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
16years-old 至 65years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Other treatment for the management of underlying disease within 20 days prior to treatment initiation. 2)Patients with previous HSCT within 6 months prior to the study HSCT. 3)Patients with serious hypersensitivity to thiotepa or busulfan. 4)Patients with active infection. 5)Patients with positive test for hepatitis B surface antigen, HBV-DNA, hepatitis C virus antibody, or HIV. 6)Patients with cardiac effusion, pleural effusion, or ascites requiring treatment. 7)Patients with active double cancer. 8)Pregnant or lactating patients. 9)Patients who the investigator or subinvestigator judged as inappropriate for trial entry.

研究者

相似试验